Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.

Veronika Buxhofer-AuschDominik WolfSiegfried SormannErnst ForjanWolfgang SchimettaBettina GisslingerSonja HeiblMaria Theresa KrauthJürgen ThieleReinhard RuckserHeinz Gisslinger

Published in: European journal of haematology (2020)

The data show clear impact of platelet lowering on the thrombotic risk in ET patients with normal WBC counts. Therefore, selective platelet lowering with anagrelide appears sufficient for thrombotic risk reduction in WHO-diagnosed ET patients lacking leukocytosis.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
pulmonary embolism
prognostic factors
peripheral blood
single cell
cell therapy